← Leaderboards
Lin Zhang
University Of Pennsylvania
$9,813,751
Attributed
$11,394,714
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,394,714 · 7
By mechanism
R01$9,023,269 · 6
P50$2,371,445 · 1
Top collaborators
- Thomas C Hamilton5 shared
- Peter J O'Dwyer5 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Roger A Greenberg$15,375,785
- Klaus H. Kaestner$80,959,526
- Haineng Xu$224,104
- Michael David Farwell$4,041,739
- Kara A Bernstein$8,200,317
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant NeoplasmsMolecularGenesCellsMalignant Neoplasm Of OvaryEpigenetic ProcessGene ExpressionPathway InteractionsIn VivoWomanPharmaceutical PreparationsResourcesGenetic TranscriptionOncologyReportingCancer CellDoseExhibitsProteinsPre-ClinicalDna Sequence AlterationCombined Modality TherapyNew Therapeutic Target
Grant awards (28)
KAT6A as a novel druggable target for cancer treatment: mechanisms and therapeutic implications in KAT6A-dependent tumors$552,763
R01 · FY2025 · CA · contact PI
Protein arginine methyltransferase inhibitors in treatment of high-grade serous ovarian cancer and triple-negative breast cancer$530,697
R01 · FY2025 · CA · contact PI
Targeting CDK7 in high-grade serous ovarian carcinoma$443,232
R01 · FY2025 · CA · contact PI
Protein arginine methyltransferase inhibitors in treatment of high-grade serous ovarian cancer and triple-negative breast cancer$530,697
R01 · FY2024 · CA · contact PI
Targeting CDK7 in high-grade serous ovarian carcinoma$421,071
R01 · FY2024 · CA · contact PI
Targeting CDK7 in high-grade serous ovarian carcinoma$434,368
R01 · FY2023 · CA · contact PI
Molecular mechanism and preclinical development of BETi and PARPi combination therapy$360,922
R01 · FY2023 · CA · contact PI
Targeting CDK7 in high-grade serous ovarian carcinoma$434,368
R01 · FY2022 · CA · contact PI
Molecular mechanism and preclinical development of BETi and PARPi combination therapy$360,922
R01 · FY2022 · CA · contact PI
Targeting CDK7 in high-grade serous ovarian carcinoma$439,860
R01 · FY2021 · CA · contact PI
Molecular mechanism and preclinical development of BETi and PARPi combination therapy$368,288
R01 · FY2021 · CA · contact PI
Molecular mechanism and preclinical development of BETi and PARPi combination therapy$368,288
R01 · FY2020 · CA · contact PI
Molecular mechanism and preclinical development of BETi and PARPi combination therapy$368,288
R01 · FY2019 · CA · contact PI
The epigenetic mechanism of long non-coding RNA in cancer$355,019
R01 · FY2019 · CA · contact PI
The epigenetic mechanism of long non-coding RNA in cancer$366,000
R01 · FY2018 · CA · contact PI
The epigenetic mechanism of long non-coding RNA in cancer$366,000
R01 · FY2017 · CA · contact PI
The epigenetic mechanism of long non-coding RNA in cancer$366,000
R01 · FY2016 · CA · contact PI
The epigenetic mechanism of long non-coding RNA in cancer$366,000
R01 · FY2015 · CA · contact PI
The role of microRNA, mir-30d, in the initiation and progression of cancer$312,379
R01 · FY2014 · CA · contact PI
Therapeutic Micro RNA Strategies for Ovarian Cancer$502,616
P50 · FY2013 · CA
The role of microRNA, mir-30d, in the initiation and progression of cancer$302,718
R01 · FY2013 · CA · contact PI
Therapeutic Micro RNA Strategies for Ovarian Cancer$426,838
P50 · FY2012 · CA
The role of microRNA, mir-30d, in the initiation and progression of cancer$322,040
R01 · FY2012 · CA · contact PI
Therapeutic Micro RNA Strategies for Ovarian Cancer$496,164
P50 · FY2011 · CA
The role of microRNA, mir-30d, in the initiation and progression of cancer$322,040
R01 · FY2011 · CA · contact PI
Therapeutic Micro RNA Strategies for Ovarian Cancer$522,716
P50 · FY2010 · CA
The role of microRNA, mir-30d, in the initiation and progression of cancer$331,309
R01 · FY2010 · CA · contact PI
Therapeutic Micro RNA Strategies for Ovarian Cancer$423,111
P50 · FY2009 · CA